Fate Therapeutics, Inc. (FATE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FATE Revenue Growth
Revenue Breakdown (FY 2023)
FATE's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
FATE Revenue Analysis (2014–2025)
As of May 8, 2026, Fate Therapeutics, Inc. (FATE) generated trailing twelve-month (TTM) revenue of $6.6 million, reflecting significant decline in growth of -26.4% year-over-year. The most recent quarter (Q4 2025) recorded $1.4 million in revenue, down 21.4% sequentially.
Looking at the longer-term picture, FATE's 5-year compound annual growth rate (CAGR) stands at -26.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $96.3 million in 2022.
Revenue diversification analysis shows FATE's business is primarily driven by Upfront Fee And Equity Premium (100%). With over half of revenue concentrated in Upfront Fee And Equity Premium, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CRSP (-88.9% YoY), NTLA (+16.9% YoY), and BEAM (+108.0% YoY), FATE has underperformed the peer group in terms of revenue growth. Compare FATE vs CRSP →
FATE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FATECurrent | $7M | -26.4% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
FATE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6.6M | -51.2% | $0 | - | $-147,704,000 | -2222.4% |
| 2024 | $13.6M | -78.5% | $13.6M | 100.0% | $-210,276,000 | -1542.6% |
| 2023 | $63.5M | -34.0% | $-93,654,000 | -147.4% | $-190,511,000 | -299.9% |
| 2022 | $96.3M | +72.4% | $82.5M | 85.7% | $-308,386,000 | -320.2% |
| 2021 | $55.8M | +77.7% | $50.0M | 89.5% | $-216,994,000 | -388.6% |
| 2020 | $31.4M | +194.3% | $-94,189,000 | -299.6% | $-128,085,000 | -407.5% |
| 2019 | $10.7M | +125.3% | $10.7M | 100.0% | $-100,727,000 | -943.1% |
| 2018 | $4.7M | +15.4% | $-51,284,000 | -1081.9% | $-67,092,000 | -1415.4% |
| 2017 | $4.1M | -6.7% | $-30,252,000 | -736.8% | $-42,125,000 | -1025.9% |
| 2016 | $4.4M | +81.1% | $-22,050,000 | -500.9% | $-31,963,000 | -726.1% |
See FATE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FATE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FATE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFATE — Frequently Asked Questions
Quick answers to the most common questions about buying FATE stock.
Is FATE's revenue growth accelerating or slowing?
FATE revenue declined -26.4% year-over-year, contrasting with the 5-year CAGR of -26.7%. TTM revenue fell to $7M. This reverses the prior growth trend.
What is FATE's long-term revenue growth rate?
Fate Therapeutics, Inc.'s 5-year revenue CAGR of -26.7% reflects the variable expansion pattern. Current YoY growth of -26.4% is below this long-term average.
How is FATE's revenue distributed by segment?
FATE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.